Industry
Biotechnology
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Loading...
Open
1.37
Mkt cap
16M
Volume
9.2K
High
1.40
P/E Ratio
-0.92
52-wk high
5.12
Low
1.36
Div yield
N/A
52-wk low
1.22
Portfolio Pulse from
November 12, 2024 | 10:00 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 12:34 pm
Portfolio Pulse from Benzinga Newsdesk
March 20, 2024 | 4:08 pm
Portfolio Pulse from Benzinga Newsdesk
March 19, 2024 | 11:05 am
Portfolio Pulse from Henry Khederian
February 09, 2024 | 7:39 pm
Portfolio Pulse from Benzinga Insights
February 09, 2024 | 5:31 pm
Portfolio Pulse from Avi Kapoor
February 09, 2024 | 5:08 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.